Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
SmallCapReview.com a leading site for news and information on small caps, penny stocks and microcaps is adding Transition Therapeutics (TTHI) to its list of stocks “On the Radar”.
Transition Therapeutics (TTHI) is a biopharmaceutical company that engages in developing therapeutics for various disease indications primarily in Canada. Its product candidates include ELND005 (AZD-103), a Phase II clinical trial product for the treatment of Alzheimers disease and neuropsychiatric disorders; TT-301 and TT-302, which are in Phase I clinical trial for the treatment of rheumatoid arthritis, Alzheimers disease, intracerebral hemorrhage, and traumatic brain injury; and TT401/402, a Phase I clinical trial product to treat diabetes.
The company also has a pipeline of preclinical and clinical drug candidates for the treatment of anti-inflammatory and metabolic indications.
It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005 (AZD-103); and Eli Lilly and Company.
TTHI Investor Highlights
Announced the exclusive licensing of worldwide rights to a novel small molecule transcriptional regulator (“TT-601”) from Eli Lilly and Company for the treatment of osteoarthritis (“OA”) pain.
Announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer’s disease (AD).
Announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a US$7 million milestone payment.
The Company’s cash and cash equivalents and short term investments were $22,942,039 at March 31, 2013 .
Announced the results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT-401 a once-weekly administered peptide, demonstrated significant improvements in glycemic control and reductions in body weight.
To learn more about TTHI visit http://www.smallcapreview.com/tthi.htm.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been compensated for its efforts with regards to Transition Therapeutics.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com.
